Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.320
+0.060 (2.65%)
Jun 18, 2026, 4:08 PM HKT
Market Cap6.64B -7.6%
Revenue (ttm)744.45M -11.7%
Net Income-173.22M
EPS-0.17
Shares Out 1.04B
PE Ration/a
Forward PEn/a
Dividend0.03 (1.38%)
Ex-Dividend DateJul 10, 2025
Volume43,753,000
Open2.250
Previous Close2.260
Day's Range2.210 - 2.780
52-Week Range2.200 - 5.290
Beta0.09
AnalystsStrong Buy
Price Target6.78 (+192.24%)
Earnings DateAug 12, 2026

About HKG:1349

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., engages in the research, development, manufacture, and sale of biopharmaceutical products in the People's Republic of China. It offers photodynamic technology drugs, such as aminolevulinic acid hydrochloride and hemoporfin for Injection; doxorubicin liposome under the Libord brand; genetic engineering drugs; and oral solid preparation technology drugs. The company was founded in 1996 and is based in Shanghai, the People's Republic of China. [Read more]

Sector Healthcare
Founded 1996
Employees 876
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 1349
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements